AX Versus AC as Adjuvant Treatment for Node-Negative Breast Cancer
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Capecitabine has shown high efficacy in metastatic and adjuvant settings. This is a
prospective, randomised trial, to compare the efficacy and safety profiles of
capecitabine-containing regimen with non- capecitabine-containing adjuvant chemotherapy
regimens for node negative breast cancer patients.